Press coverage about Sarepta Therapeutics (NASDAQ:SRPT) has trended somewhat positive on Friday, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sarepta Therapeutics earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 93 out of 100, meaning that recent media coverage is extremely likely to have an effect on the stock’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of “Buy” by Analysts (americanbankingnews.com)
- The Technical Condition Changes For Sarepta Therapeutics, Inc. (SRPT), Progenics Pharmaceuticals, Inc. (PGNX) – AllStockNews (allstocknews.com)
- Sarepta Therapeutics, Inc. (SRPT) stock stream of 1.51% – Stocks Gallery (stocksgallery.com)
- Sarepta Therapeutics, Inc. (SRPT) Expected to Post Quarterly Sales of $37.59 Million (americanbankingnews.com)
- Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Expected to Post Earnings of -$0.89 Per Share (americanbankingnews.com)
Sarepta Therapeutics (NASDAQ:SRPT) traded up 3.57% during trading on Friday, hitting $38.34. 1,726,111 shares of the stock were exchanged. Sarepta Therapeutics has a one year low of $24.31 and a one year high of $63.73. The company’s market cap is $2.47 billion. The stock’s 50 day moving average is $37.03 and its 200-day moving average is $32.83.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.46. The company had revenue of $35.01 million during the quarter, compared to the consensus estimate of $22.52 million. During the same quarter last year, the company earned ($1.19) earnings per share. The business’s revenue was up 350000.0% on a year-over-year basis. On average, equities research analysts expect that Sarepta Therapeutics will post ($1.16) earnings per share for the current fiscal year.
A number of research firms have recently weighed in on SRPT. BidaskClub lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Zacks Investment Research upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. William Blair restated an “outperform” rating on shares of Sarepta Therapeutics in a research report on Thursday, July 27th. Janney Montgomery Scott increased their price objective on shares of Sarepta Therapeutics from $65.00 to $73.00 and gave the company a “fair value” rating in a report on Monday, July 24th. Finally, Robert W. Baird reissued an “outperform” rating and issued a $96.00 price target (down from $102.00) on shares of Sarepta Therapeutics in a research note on Friday, July 21st. Eight investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $61.28.
COPYRIGHT VIOLATION WARNING: This article was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.com-unik.info/2017/08/11/sarepta-therapeutics-srpt-earns-media-impact-rating-of-0-18-updated-updated-updated.html.
In related news, SVP Alexander Cumbo sold 5,918 shares of the company’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $242,638.00. Following the completion of the sale, the senior vice president now owns 22,793 shares in the company, valued at $934,513. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Shamim Ruff sold 12,138 shares of the stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $42.97, for a total value of $521,569.86. Following the transaction, the senior vice president now owns 27,312 shares of the company’s stock, valued at $1,173,596.64. The disclosure for this sale can be found here. In the last three months, insiders sold 78,056 shares of company stock worth $3,224,208. Insiders own 9.60% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
What are top analysts saying about Sarepta Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sarepta Therapeutics Inc. and related companies.